RubÃ©n FernÃ¡ndez-Santiago

List of Publications by Year
in descending order

62 papers	3,772 citations	186265 28 h-index	149698 56 g-index
63 all docs	63 docs citations	63 times ranked	5775 citing authors

#	Article	IF	Citations
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
2	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
3	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of nonâ€Ashkenazi Jewish ancestry. Movement Disorders, 2017, 32, 1432-1438.	3.9	126
4	Identification of blood serum microâ€RNAs associated with idiopathic and LRRK2 Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
5	Aberrant epigenome in <scp>iPSC</scp> â€derived dopaminergic neurons from Parkinson's disease patients. EMBO Molecular Medicine, 2015, 7, 1529-1546.	6.9	117
6	Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology, 2016, 86, 994-999.	1.1	114
7	Motor and nonmotor heterogeneity of LRRK2â€related and idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1192-1202.	3.9	102
8	Advances in Parkinsonâ€™s Disease: 200 Years Later. Frontiers in Neuroanatomy, 2018, 12, 113.	1.7	102
9	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
10	Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. Journal of Medical Genetics, 2009, 46, 840-846.	3.2	70
11	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. PLoS ONE, 2015, 10, e0132368.	2.5	67
12	Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. Journal of Neurology, 2009, 256, 1337-1342.	3.6	60
13	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	3.9	57
14	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
15	MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiology of Aging, 2018, 69, 283-291.	3.1	55
16	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	55
17	The <scp>MC1R</scp> melanoma risk variant p.<scp>R160W</scp> is associated with <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 77, 889-894.	5.3	52
18	Micro<scp>RNA</scp> association with synucleinopathy conversion in rapid eye movement behavior disorder. Annals of Neurology, 2015, 77, 895-901.	5.3	50

#	Article	IF	Citations
19	The prodromal phase of leucineâ€rich repeat kinase 2â€“associated Parkinson disease: Clinical and imaging Studies. Movement Disorders, 2017, 32, 726-738.	3.9	48
20	Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Human Molecular Genetics, 2012, 21, 3568-3574.	2.9	47
21	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
22	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
23	Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinsonâ€™s disease. Cell Death and Disease, 2014, 5, e1364-e1364.	6.3	40
24	The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against Î±-Synuclein-Induced Toxicity. Molecular Neurobiology, 2018, 55, 7533-7552.	4.0	40
25	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. Journal of Molecular Neuroscience, 2012, 48, 245-247.	2.3	34
26	Discovering the 3â€² UTR-mediated regulation of alpha-synuclein. Nucleic Acids Research, 2017, 45, 12888-12903.	14.5	32
27	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 46, 16-23.	2.2	32
28	Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology, 2016, 86, 1072-1073.	1.1	30
29	Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. Neurology, 2006, 66, 1929-1931.	1.1	29
30	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
31	Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease. EBioMedicine, 2019, 48, 554-567.	6.1	28
32	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. Parkinsonism and Related Disorders, 2019, 65, 3-12.	2.2	26
33	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 764-767.	1.9	25
34	Î±â€synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucineâ€rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Movement Disorders, 2018, 33, 637-641.	3.9	25
35	Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging, 2019, 11, 3750-3767.	3.1	25
36	No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiology of Aging, 2011, 32, 551.e1-551.e4.	3.1	22

#	Article	IF	Citations
37	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	3.1	22
38	Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinsonâ€™s disease. Journal of Translational Medicine, 2018, 16, 160.	4.4	22
39	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
40	Peripheral insulin and amylin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, 91-96.	2.2	20
41	MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinsonâ€™s Disease Patients. Molecular Neurobiology, 2019, 56, 2092-2100.	4.0	17
42	Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinsonâ€™s disease patients. Clinical Epigenetics, 2019, 11, 108.	4.1	16
43	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
44	A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 459-463.	2.8	15
45	<scp>MicroRNA</scp> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. Movement Disorders, 2020, 35, 1873-1879.	3.9	15
46	CCAAT/enhancer binding protein Î´ is a transcriptional repressor of Î±-synuclein. Cell Death and Differentiation, 2020, 27, 509-524.	11.2	14
47	Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models. Stem Cells International, 2016, 2016, 1-16.	2.5	13
48	Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations. Neurobiology of Aging, 2018, 65, 206-216.	3.1	13
49	Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. European Journal of Neurology, 2011, 18, e32-e32.	3.3	12
50	MAPT association with REM sleep behavior disorder. Neurology: Genetics, 2017, 3, e131.	1.9	10
51	Differential Phosphoâ€Signatures in Blood Cells Identify <scp>LRRK2 G2019S</scp> Carriers in Parkinson's Disease. Movement Disorders, 2022, 37, 1004-1015.	3.9	9
52	What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?. Ageing Research Reviews, 2022, 79, 101648.	10.9	9
53	Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 1063.	5.1	8
54	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinsonâ€™s disease patients. Npj Parkinson's Disease, 2022, 8, 27.	5.3	8

#	Article	IF	Citations
55	Transcriptomic differences in MSA clinical variants. Scientific Reports, 2020, 10, 10310.	3.3	7
56	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
57	Reply. Annals of Neurology, 2016, 79, 161-163.	5.3	3
58	Parkinsonâ€™s disease as a systemic pathology. Aging, 2019, 11, 1081-1082.	3.1	3
59	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	2.2	2
60	Reply. Annals of Neurology, 2015, 78, 153-154.	5.3	1
61	Transcriptome analysis in LRRK2 and idiopathic Parkinsonâ€™s disease at different glucose levels. Npj Parkinson's Disease, 2021, 7, 109.	5.3	1
62	Reply. Annals of Neurology, 2016, 79, 868-868.	5.3	0